MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

PTC Therapeutics Company Profile (NASDAQ:PTCT)

Consensus Ratings for PTC Therapeutics (NASDAQ:PTCT) (?)
Ratings Breakdown: 8 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $46.91 (532.20% upside)

Analysts' Ratings History for PTC Therapeutics (NASDAQ:PTCT)
Show:
DateFirmActionRatingPrice TargetActions
4/18/2016RBC CapitalReiterated RatingSector Perform$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016OppenheimerReiterated RatingBuy$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/23/2016WedbushReiterated RatingNeutral$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016Credit SuisseReiterated RatingOutperform$36.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016BarclaysBoost Price TargetOverweight$40.00 -> $100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Bank of AmericaDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Citigroup Inc.DowngradeBuy -> Neutral$90.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Jefferies GroupUpgradeUnderperform -> Hold$18.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$81.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/16/2015Roth CapitalReiterated RatingHold$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2015Deutsche BankReiterated RatingBuy$115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 4/30/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha